Advertisement
Canada markets open in 1 hour 51 minutes

  • S&P/TSX

    21,516.90
    -94.40 (-0.44%)
     

  • S&P 500

    5,487.03
    +13.80 (+0.25%)
     

  • DOW

    38,834.86
    +56.76 (+0.15%)
     

  • CAD/USD

    0.7293
    -0.0004 (-0.06%)
     

  • CRUDE OIL

    81.70
    +0.13 (+0.16%)
     

  • Bitcoin CAD

    90,887.89
    +1,546.48 (+1.73%)
     

  • CMC Crypto 200

    1,377.70
    -4.96 (-0.36%)
     

  • GOLD FUTURES

    2,353.40
    +6.50 (+0.28%)
     

  • RUSSELL 2000

    2,025.23
    +3.22 (+0.16%)
     

  • 10-Yr Bond

    4.2170
    0.0000 (0.00%)
     

  • NASDAQ futures

    20,042.00
    +122.75 (+0.62%)
     

  • VOLATILITY

    12.56
    +0.08 (+0.64%)
     

  • FTSE

    8,234.61
    +29.50 (+0.36%)
     

  • NIKKEI 225

    38,633.02
    +62.26 (+0.16%)
     

  • CAD/EUR

    0.6797
    +0.0010 (+0.15%)
     

Dynavax to Present at Upcoming Investor Conferences

PR Newswire
·1 min read

EMERYVILLE, Calif. , May 28, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the following upcoming investor conferences during the month of June:

(PRNewsfoto/Dynavax Technologies)
(PRNewsfoto/Dynavax Technologies)

  • William Blair 44th Annual Growth Stock Conference on Tuesday, June 4 at 1:20 p.m. CT

  • Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10 at 4:00 p.m. ET

The presentations will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations.

ADVERTISEMENT

About Dynavax

Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant with adjuvanted vaccine clinical programs for shingles and Tdap, and through global collaborations, currently focused on adjuvanted vaccines for COVID-19, plague, seasonal influenza and universal influenza. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn and Twitter.

For Investors/Media:
Paul Cox
pcox@dynavax.com 
510-665-0499

Nicole Arndt
narndt@dynavax.com,  510-665-7264

 

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-present-at-upcoming-investor-conferences-302157153.html

SOURCE Dynavax Technologies